173 related articles for article (PubMed ID: 35031634)
21. Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study.
Carlos Souto Maior Borba MA; de Mendonça Batista P; Falcão Almeida M; do Carmo Rego MA; Brandão Serra F; Barbour Oliveira JC; Nakajima K; Silva Julian G; Amorim G
Sci Rep; 2023 Sep; 13(1):15785. PubMed ID: 37737435
[TBL] [Abstract][Full Text] [Related]
22. Comparison of outcomes between metaplastic and triple-negative breast cancer patients.
Polamraju P; Haque W; Cao K; Verma V; Schwartz M; Klimberg VS; Hatch S; Niravath P; Butler EB; Teh BS
Breast; 2020 Feb; 49():8-16. PubMed ID: 31675684
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Du F; Yuan P; Luo Y; Wang J; Ma F; Cai R; Fan Y; Li Q; Zhang P; Xu B
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):788-92. PubMed ID: 26813602
[TBL] [Abstract][Full Text] [Related]
24. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
Ghebeh H; Elshenawy MA; AlSayed AD; Al-Tweigeri T
Immunotherapy; 2022 Mar; 14(4):189-199. PubMed ID: 34984928
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience.
Kumar S; Furrukh M; Al-Baimani K; Al-Ajmi A; Burney IA; Al-Moundhri MS
Sultan Qaboos Univ Med J; 2019 Aug; 19(3):e209-e216. PubMed ID: 31728218
[TBL] [Abstract][Full Text] [Related]
27. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
[TBL] [Abstract][Full Text] [Related]
28. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
29. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
30. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
[TBL] [Abstract][Full Text] [Related]
31. Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney.
Naher S; Tognela A; Moylan E; Adams DH; Kiely BE
Intern Med J; 2018 May; 48(5):567-572. PubMed ID: 28967175
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
33. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
Cabel L; Carton M; Pistilli B; Dalenc F; Vanlemnens L; Levy C; Jacot W; Debled M; Loeb A; Hennequin A; De la Motte Rouge T; Laborde L; Laurent C; Chamorey E; Parent D; Petit T; Mouret-Reynier MA; Campone M; Perrocheau G; Labreveux C; Bachelot T; Robain M; Lerebours F
Breast; 2021 Apr; 56():18-25. PubMed ID: 33561617
[TBL] [Abstract][Full Text] [Related]
34. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Zangardi ML; Spring LM; Nagayama A; Bardia A
Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
[TBL] [Abstract][Full Text] [Related]
35. Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016.
Sieluk J; Haiderali A; Huang M; Yang L; Hirshfield KM
Future Oncol; 2021 Mar; 17(9):1039-1054. PubMed ID: 33261515
[No Abstract] [Full Text] [Related]
36. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Vernieri C; Mennitto A; Prisciandaro M; Huber V; Milano M; Rinaldi L; Cona MS; Maggi C; Ferrari B; Manoukian S; Mariani G; Bianchi G; Capri G; Rivoltini L; de Braud F
Sci Rep; 2018 Jun; 8(1):8703. PubMed ID: 29880896
[TBL] [Abstract][Full Text] [Related]
37. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
39. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
